| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.045 | 0.4 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.4 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |